Bernstein Initiates Coverage On Revolution Medicines with Market Perform Rating, Announces Price Target of $151

Benzinga Newsdesk www.benzinga.com Neutral 65.1%

Neg 0% Neu 65.1% Pos 0%

Bernstein analyst Jeffrey Walch initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Market Perform rating and announces Price Target of $151.